TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06534502: Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures

Sponsor: Azurity Pharmaceuticals · Phase: PHASE4 · Area: CNS_NEUROLOGY · Target Enrollment: 40 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$9,932,800

Rescue Site Savings

+$6,549,440

Unlock Full NCT06534502 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06534502 Rescue Dossier →